OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Obsidian Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$11.94+0.17 (+1.44%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Obsidian Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah | 5,957,103 | 9.70% | 13G (passive) | Aug 3, 2026 |
| Paradigm BioCapital Advisors LP | 4,101,576 | 6.60% | 13G (passive) | Sep 28, 2026 |
| Deep Track Capital, LP | 3,315,605 | 5.37% | 13G (passive) | Aug 4, 2026 |
| Novo Holdings A/S | 3,123,992 | 5.10% | 13G (passive) | Aug 3, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Madan Jagasia | Chief Executive Officer, Director | – | – | Aug 5, 2026 |
| Julie B. Feder | Chief Financial Officer | – | – | Aug 3, 2026 |
| Parameswaran Hari | Chief Medical Officer | – | – | Aug 3, 2026 |
| Matthew Norkunas | Director | 30,937 | 0.05% | Aug 5, 2026 |
| Maria Fardis | Director | – | – | Aug 5, 2026 |
| Peter Barrett | Director | – | – | Aug 5, 2026 |
| Heidi Hagen | Director | – | – | Aug 5, 2026 |
| Robert W. Ross | Director | – | – | Aug 5, 2026 |